Ensidnib

Ensidnib uses and dosage

Ensidnib (Enasidenib), generic Idhifa is a prescription medicine used to treat patients with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatments. Enasidenib works by helping patient's bone marrow grow normal blood cells so patient will need fewer blood transfusions. Ensidnib is manufactured by TLPH Pharma Ltd. In Laos. Enasidenib has to take orally usually once daily with/ without food.

Ensidnib side effects

The most common adverse reactions of Enasidenib are: Diarrhea, nausea, vomiting, change in taste, or loss of appetite

Originator brand

Idhifa by Bristol myers squibb

Made by

TLPH Pharma

This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.